Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kowa Applies for Peretinoin in Japan
January 31, 2011
- MSD to Propose Its Own Anti-Allergy Drugs Alone or in Combination for Pollinosis
January 31, 2011
- Yasuchika Hasegawa to Step Down as JPMA President, Isao Teshirogi to Succeed
January 31, 2011
- Korosho Cautions on the Use of Botulinum Toxin Types A, B
January 31, 2011
- Dialysis Costs Kyokaikenpo ¥175 Bil. Annually
January 31, 2011
- JPMA to Finalize GL for Disclosure of Funds Offered to Medical Institutions
January 31, 2011
- PMDA to Transfer GMP Compliance Inspection Power Earlier to Prefectures
January 31, 2011
- Sanofi-aventis Signs R&D Collaboration Agreements with UCSF
January 31, 2011
- JACDS to Clarify Its Stance on Points Granted for Copayments of Dispensing Fees
January 31, 2011
- Roche Diagnostics Obtains Approval for HER2 Gene Amplification Kit
January 31, 2011
- Teijin Pharma to Launch TMX-67 in Emerging Countries in 2013-2014
January 24, 2011
- Market for Drugs for Alzheimer's Disease to Reach ¥290 Bil. in 2020: Seed Planning Survey
January 24, 2011
- FJPWA to Do Utmost for Full Introduction of Premium for New Drug Development: Chairman Bessho
January 24, 2011
- 76 Actos Generics Approved from 27 Companies
January 24, 2011
- Qol Considers Introducing Point Cards for Drug Dispensing Services
January 24, 2011
- Pfizer to Market Generics of Over 20 APIs in 2011
January 24, 2011
- classA Network Considers Introducing Point Service Program
January 24, 2011
- Small Generic Makers to Increasingly Specialize in Development, Manufacturing: JGA President Sawai
January 24, 2011
- JACDS to Call on Members to Temporarily Refrain from Offering Points for Dispensing Services
January 24, 2011
- Mr Hosokawa Reappointed Health Minister
January 24, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…